Biosimilars Council urges SCOTUS to limit biologics exclusivity period

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), has filed a brief in support of Sandoz’s petition for certiorari in the pending Sandoz v Amgen case.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circuit erred in Sandoz v Amgen, says solicitor general

28 February 2017 The US Court of Appeals for the Federal Circuit erred in holding that biosimilar applicants must give 180 days’ pre-marketing notice after an application has been approved by the US Food and Drug Administration, according to the acting solicitor general.

Americas

Dow asks SCOTUS to review $445m award dispute

15 September 2017 Agriculture company Dow has asked the US Supreme Court to review a dispute centring on damages for infringement of patents related to genetically engineered soybeans.

More on this story

Americas

Fed Circuit erred in Sandoz v Amgen, says solicitor general

Americas

Dow asks SCOTUS to review $445m award dispute

15 September 2017 Agriculture company Dow has asked the US Supreme Court to review a dispute centring on damages for infringement of patents related to genetically engineered soybeans.

More on this story

Americas

Fed Circuit erred in Sandoz v Amgen, says solicitor general

Americas

Dow asks SCOTUS to review $445m award dispute

15 September 2017 Agriculture company Dow has asked the US Supreme Court to review a dispute centring on damages for infringement of patents related to genetically engineered soybeans.